Sigmoid Pharma - now known as Sublimity Therapeutics has closed an enormous $64m round of financing to fund the clinical development of a new drug.
Globe News Wire - Sigmoid Pharma Limited Announces a Strategic Collaboration with Dr. Falk Pharma GmBH Please link to the article below which was posted in Apr 2017 by globenewswire.com. Sigmoid Pharma develop innovative pharmaceuticals for gastrointestinal and immunological diseases, they have entered into an exclusive agreement with Dr. Falk Pharma GmBH advance Sigmoid’s SmPill® cyclosporine franchise in Europe. As part of the agreement Sigmoid are to receive up-front equity investment, development funding as well as clinical and operational support. You can access further information by reading the full article by clicking on the button below. Globe News Wire [...]
Genetic Engineering & Biotechnology News - Sigmoid Pharma to Acquire Freund Pharmatec Please link to the article below by which was posted in Feb 2016 by genengnews.com website. Sigmoid Pharma is to acquire Freund Pharmatec for an undisclosed price. Freund is a drug delivery technology company and has committed to continue customer-funded R&D programs under Sigmoid management. Sigmoid develop drugs for immunological diseases and GI disorders and the acquisition of Freund will enable them to advance their lead programs through late-stage clinical development. You can read the full article by clicking on the button below. Gen Eng News - [...]
FirstWord Pharma - referenced from The Irish Times Please link to the article below which was posted in Sept 2014 by firstwordpharma.com website. The post refers to an Irish Times article reporting that Sigmoid Pharma entered into an exclusive licence agreement with Pendopharm to commercialise its product to treat ulcerative colitis. The agreement amounts to a €5m investment. You can read the full article by clicking on the button below. FirstWord Pharma Article - "Sigmoid Pharma raises €5m investment from Pendopharm"